⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 20, 2024

[Selection of postoperative adjuvant therapy for patients with stage IB lung adenocarcinoma: analysis of 653 cases].

Leilei Shen Yue Chen Tae-Jin Yun Jun Guo Yang Liu T Zhang Chaoyang Liang Y Liu

View at Publisher

Ask AI

Bookmark

Share

Abstract

To explore the optimal postoperative adjuvant regimens for patients with stage IB lung adenocarcinoma.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shen et al. (2024) studied this question.

synapsesocial.com/papers/68e695cbb6db64358761ca09 https://doi.org/10.12122/j.issn.1673-4254.2024.05.22

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Histopathologic pattern and molecular risk stratification are associated with prognosis in patients with stage IB lung adenocarcinoma2024 · 1 citations
2Real-world efficacy of adjuvant therapy for totally resected stage I lung adenocarcinoma patients with pathological high-risk factors: propensity score analysis2024 · 3 citations
3Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection2024 · 12 citations
4Establishment and validation of a clinicopathological prediction model for postoperative recurrence of stage IA lung adenocarcinoma2024
5Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633RCT · 2006 · 178 citations

Benefits of adjuvant chemotherapy in elderly patients with stage IB–IIIB non-small cell lung cancer: a propensity-matched analysis2024
Assessing risk and benefit of adjuvant therapy in stage IB NSCLC.2026
Analysis of risk factors for postoperative recurrence of stage IA lung adenocarcinoma2025

More from Chinese PLA General Hospital

More from Hainan General Hospital